Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKMs NMIMS, V.L.Mehta Road, Vile Parle (W), Mumbai, Maharashtra, 400056, India.
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKMs NMIMS, V.L.Mehta Road, Vile Parle (W), Mumbai, Maharashtra, 400056, India.
Eur J Pharmacol. 2021 Dec 15;913:174638. doi: 10.1016/j.ejphar.2021.174638. Epub 2021 Nov 18.
Cerebral stroke, commonly caused due to hindrance in blood flow, is broadly classified into two categories-ischemic and haemorrhagic strokes. The onset of stroke triggers multiple mechanisms causing inflammation, generation of free radicals and protein damage leading to apoptosis of neuronal cells. The current therapies available for cerebral strokes involve use of complex surgical treatments and tissue plasminogen activator which increases the risk of internal bleeding, brain edema and cerebral damage, thereby restricting their use in clinical setting. The alarming need to develop safe, effective, target specific systems which, promote neuronal growth and reduce cerebral inflammation can be accomplished with use of biotechnological approaches. The article gives an insight to biotechnology-based advancements for tissue plasminogen activators, cell penetrating peptides, growth factors, ribonucleic acid systems and monoclonal antibodies for cerebral stroke. We also emphasis on challenges and future perspective of biotechnology-based therapeutics for better management of stroke.
脑卒中，通常由血流受阻引起，广泛分为缺血性卒中和出血性卒中两类。脑卒中的发作引发多种机制，导致炎症、自由基生成和蛋白质损伤，从而导致神经元细胞凋亡。目前用于治疗脑卒中的方法包括使用复杂的手术治疗和组织型纤溶酶原激活物，这会增加内出血、脑水肿和脑损伤的风险，从而限制了它们在临床环境中的应用。因此，迫切需要开发安全、有效、靶向特定系统，促进神经元生长并减轻脑炎症，这可以通过生物技术方法来实现。本文介绍了基于生物技术的组织型纤溶酶原激活物、细胞穿透肽、生长因子、核糖核酸系统和单克隆抗体在治疗脑卒中方面的进展。我们还强调了基于生物技术的治疗方法在更好地管理脑卒中方面所面临的挑战和未来展望。
